Business Context and Reporting Period
This Form 8-K Current Report is filed by Renovaro Inc. (not Lunai Bioworks Inc.) for the reporting period ending July 9, 2025. The filing details a material definitive agreement and unregistered sales of equity securities involving the restructuring of existing debt and the issuance of common stock to accredited investors.
Key Financial Metrics and Transaction Details
- Debt Eliminated: $9.7 million in outstanding secured promissory notes.
- New Debt Issued: $16.1 million in convertible promissory notes (representing a 65% premium over the principal and interest of the secured notes).
- Equity Issued: 53.6 million shares of common stock.
- Conversion Price: $0.30 per share.
- Cash Proceeds: $0 (The transaction involved no cash proceeds to the Company).
- Interest: The new Convertible Notes do not bear interest.
- Maturity Date: July 31, 2025 (for the Convertible Notes prior to conversion).
Material Changes Versus Prior Period
The filing reports a significant change in the Company's capital structure rather than operational performance metrics. The primary material change is the conversion of $9.7 million in secured indebtedness into equity. This transaction eliminated a specific liability and increased the number of outstanding shares by 53.6 million. The filing text does not provide comparative revenue, profit, or cash flow data for prior periods.
Guidance, Outlook, and Management Commentary
Management stated that the exchange was completed to restructure the Company's debt obligations and provide additional flexibility to support strategic initiatives. The transaction was structured to avoid triggering stockholder approval requirements under Nasdaq Listing Rule 5635(d) because the conversion price represented a premium to the closing stock price on the date of execution. The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the standard disclosure that the press release information is not deemed "filed" for liability purposes.
Investor Verification Checklist
- Verify the exact number of outstanding shares post-issuance to assess dilution impact.
- Confirm the status of the 53.6 million shares issuance (expected on or before July 11, 2025).
- Review the attached Exhibits 99.1, 99.2, and 99.3 for specific terms of the Exchange Agreement and Convertible Notes.
- Check subsequent filings for any changes in the Company's liquidity position following this non-cash transaction.
- Note that the filing explicitly states no cash proceeds were received; verify if this impacts short-term working capital needs.